189 related articles for article (PubMed ID: 9649135)
1. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.
Bonfrer JM; Korse CM; Nieweg OE; Rankin EM
Br J Cancer; 1998 Jun; 77(12):2210-4. PubMed ID: 9649135
[TBL] [Abstract][Full Text] [Related]
2. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
3. Monitoring malignant melanoma with the S-100B tumour marker.
Bonfrer JM; Korse CM
Recent Results Cancer Res; 2001; 158():149-57. PubMed ID: 11092042
[TBL] [Abstract][Full Text] [Related]
4. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
5. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
6. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
7. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
8. S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls.
de Kruijk JR; Leffers P; Menheere PP; Meerhoff S; Twijnstra A
Acta Neurol Scand; 2001 Mar; 103(3):175-9. PubMed ID: 11240565
[TBL] [Abstract][Full Text] [Related]
9. A new optical immunoassay for detection of S-100B protein in whole blood.
Ettinger A; Laumark AB; Ostroff RM; Brundell J; Baumgartner WA; Razumovsky AY
Ann Thorac Surg; 1999 Dec; 68(6):2196-201. PubMed ID: 10617002
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
11. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
12. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
[TBL] [Abstract][Full Text] [Related]
13. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
14. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum S-100B in malignant melanoma.
Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
[TBL] [Abstract][Full Text] [Related]
16. S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients.
Raabe A; Kopetsch O; Woszczyk A; Lang J; Gerlach R; Zimmermann M; Seifert V
Neurol Res; 2004 Jun; 26(4):440-5. PubMed ID: 15198874
[TBL] [Abstract][Full Text] [Related]
17. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma.
Biberthaler P; Mussack T; Wiedemann E; Kanz KG; Koelsch M; Gippner-Steppert C; Jochum M
World J Surg; 2001 Jan; 25(1):93-7. PubMed ID: 11213162
[TBL] [Abstract][Full Text] [Related]
19. Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia.
Rundgren M; Karlsson T; Nielsen N; Cronberg T; Johnsson P; Friberg H
Resuscitation; 2009 Jul; 80(7):784-9. PubMed ID: 19467754
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of cerebrospinal fluid neuron-specific enolase and S-100b protein in Guillain-Barré syndrome.
Mokuno K; Kiyosawa K; Sugimura K; Yasuda T; Riku S; Murayama T; Yanagi T; Takahashi A; Kato K
Acta Neurol Scand; 1994 Jan; 89(1):27-30. PubMed ID: 8178624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
